

TEKLA LIFE SCIENCES INVESTORS
Form N-PX
August 30, 2017

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

OMB APPROVAL
OMB Number: 3235-0582
Expires: March 31, 2018
Estimated average burden
hours per response.....7.2

Washington, D.C. 20549

FORM N-PX

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

Laura Woodward

Tekla Life Sciences Investors

100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/16-6/30/17**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

*Vote Summary***ACCELERATE DIAGNOSTICS**

Security	00430H102	Meeting Type	Annual
Ticker Symbol	AXDX	Meeting Date	04-May-2017
Record Date	15-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	LAWRENCE MEHREN	For	For
	2	MARK MILLER	For	For
	3	JOHN PATIENCE	For	For
	4	JACK SCHULER	For	For
	5	MATTHEW STROBECK, PH.D.	For	For
	6	FRANK J.M. TEN BRINK	For	For
	7	TOM BROWN	For	For
2.	TO APPROVE THE THIRD AMENDMENT TO THE COMPANY S 2012 OMNIBUS EQUITY INCENTIVE PLAN AND REAPPROVE THE MATERIAL TERMS OF THE PLAN FOR PURPOSES OF SECTION 162(M) OF THE INTERNAL REVENUE CODE OF 1986.	Management	For	For
3.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT PUBLIC ACCOUNTANTS OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

ACCELERON PHARMA INC.

Security	00434H108	Meeting Type	Annual
Ticker Symbol	XLRN	Meeting Date	01-Jun-2017
Record Date	04-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	JEAN M. GEORGE	For	For
	2	GEORGE GOLUMBESKI, PH.D	For	For
	3	THOMAS A. MCCOURT	For	For
	4	FRANCOIS NADER, M.D.	For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
3.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING	Management	For	For

DECEMBER 31, 2017.

ADAPT IMMUNE THERAPEUTICS PLC

Security	00653A107	Meeting Type	Annual
Ticker Symbol	ADAP	Meeting Date	21-Jun-2017
Record Date	04-May-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	TO RE-ELECT AS A DIRECTOR, BARBARA DUNCAN, WHO RETIRES IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
2.	TO RE-ELECT AS A DIRECTOR, GILES KERR, WHO RETIRES IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
3.	TO RE-ELECT AS A DIRECTOR, TAL ZAKS, WHO RETIRES IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
4.	TO RE-ELECT AS A DIRECTOR, ALI BEHBAHANI, WHO RETIRES BY ROTATION IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
5.	TO RE-ELECT AS A DIRECTOR, PETER THOMPSON, WHO RETIRES BY ROTATION IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
6.	TO RE-APPOINT KPMG LLP AS OUR U.K. STATUTORY AUDITORS UNDER THE ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For
7.	TO AUTHORIZE THE AUDIT COMMITTEE TO DETERMINE OUR U.K. ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For
8.	TO RECEIVE THE U.K. STATUTORY ANNUAL ACCOUNTS AND REPORTS FOR ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For
9.	TO RECEIVE AND APPROVE OUR U.K. STATUTORY DIRECTORS REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2016.	Management	For	For
10.	TO AUTHORISE THE DIRECTORS UNDER SECTION 551 OF THE U.K. COMPANIES ACT 2006 (THE 2006 ACT) TO ALLOT ORDINARY SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR OR TO CONVERT ANY SECURITY INTO ORDINARY SHARES.	Management	For	For
11.	TO AUTHORISE THE DIRECTORS TO ALLOT ORDINARY SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR OR CONVERT ANY SECURITY INTO ORDINARY ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AKORN, INC.

Security	009728106	Meeting Type	Special
Ticker Symbol	AKRX	Meeting Date	16-Dec-2016
Record Date	28-Oct-2016		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	PROPOSAL TO APPROVE THE AKORN, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN.	Management	For	For
2.	PROPOSAL TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE AKORN, INC. 2014 STOCK OPTION PLAN.	Management	For	For

AKORN, INC.

Security	009728106	Meeting Type	Annual
Ticker Symbol	AKRX	Meeting Date	27-Apr-2017
Record Date	13-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 JOHN KAPOOR, PHD		For	For
	2 KENNETH ABRAMOWITZ		For	For
	3 ADRIENNE GRAVES, PHD		For	For
	4 RONALD JOHNSON		For	For
	5 STEVEN MEYER		For	For
	6 TERRY ALLISON RAPPUHN		For	For
	7 BRIAN TAMBI		For	For
	8 ALAN WEINSTEIN		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF BDO USA, LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	PROPOSAL TO APPROVE THE 2017 OMNIBUS INCENTIVE COMPENSATION PLAN.	Management	For	For
4.	PROPOSAL TO APPROVE, THROUGH A NON- BINDING ADVISORY VOTE, THE FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON THE COMPANY S EXECUTIVE COMPENSATION PROGRAMS.	Management	1 Year	For
5.	PROPOSAL TO APPROVE, THROUGH A NON- BINDING ADVISORY VOTE, THE COMPANY S EXECUTIVE COMPENSATION PROGRAM AS DESCRIBED IN THE COMPANY S 2017 PROXY STATEMENT.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AKORN, INC.

Security	009728106	Meeting Type	Special
Ticker Symbol	AKRX	Meeting Date	19-Jul-2017
Record Date	09-Jun-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	TO APPROVE THE AGREEMENT AND PLAN OF MERGER, DATED AS OF APRIL 24, 2017, BY AND AMONG FRESENIUS KABI AG, QUERCUS ACQUISITION, INC., AKORN, INC. AND, SOLELY FOR PURPOSES OF ARTICLE VIII THEREIN, FRESENIUS SE & CO. KGAA.	Management	For	For
2.	TO APPROVE, BY NON-BINDING, ADVISORY VOTE, THE COMPENSATION THAT MAY BE PAID OR MAY BECOME PAYABLE TO AKORN, INC. S NAMED EXECUTIVE OFFICERS IN CONNECTION WITH, OR FOLLOWING, THE CONSUMMATION OF THE MERGER CONTEMPLATED BY THE AGREEMENT AND PLAN OF MERGER.	Management	For	For
3.	TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING TO A LATER DATE OR TIME, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IN THE EVENT THERE ARE INSUFFICIENT VOTES AT THE TIME OF THE SPECIAL MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF TO ADOPT THE AGREEMENT AND PLAN OF MERGER.	Management	For	For

ALEXION PHARMACEUTICALS, INC.

Security	015351109	Meeting Type	Annual
Ticker Symbol	ALXN	Meeting Date	10-May-2017
Record Date	14-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: FELIX J. BAKER	Management	For	For
1B.	ELECTION OF DIRECTOR: DAVID R. BRENNAN	Management	For	For
1C.	ELECTION OF DIRECTOR: M. MICHELE BURNS	Management	For	For
1D.	ELECTION OF DIRECTOR: CHRISTOPHER J. COUGHLIN	Management	For	For
1E.	ELECTION OF DIRECTOR: LUDWIG N. HANTSON	Management	For	For
1F.	ELECTION OF DIRECTOR: JOHN T. MOLLEN	Management	For	For
1G.	ELECTION OF DIRECTOR: R. DOUGLAS NORBY	Management	For	For
1H.	ELECTION OF DIRECTOR: ALVIN S. PARVEN	Management	For	For
1I.	ELECTION OF DIRECTOR: ANDREAS RUMMELT	Management	For	For
1J.	ELECTION OF DIRECTOR: ANN M. VENEMAN	Management	For	For
2.	TO APPROVE ALEXION S 2017 INCENTIVE PLAN.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

3.	RATIFICATION OF APPOINTMENT BY THE BOARD OF DIRECTORS OF PRICEWATERHOUSECOOPERS LLP AS ALEXION'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.	Management	For	For
4.	APPROVAL OF A NON-BINDING ADVISORY VOTE OF THE 2016 COMPENSATION PAID TO ALEXION'S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For
6.	TO REQUEST THE BOARD IMPLEMENT CONFIDENTIAL SHAREHOLDER VOTING ON EXECUTIVE PAY MATTERS.	Shareholder	Against	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ALLERGAN PLC

Security	G0177J108	Meeting Type	Annual
Ticker Symbol	AGN	Meeting Date	04-May-2017
Record Date	08-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: NESLI BASGOZ, M.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: PAUL M. BISARO	Management	For	For
1C.	ELECTION OF DIRECTOR: JAMES H. BLOEM	Management	For	For
1D.	ELECTION OF DIRECTOR: CHRISTOPHER W. BODINE	Management	For	For
1E.	ELECTION OF DIRECTOR: ADRIANE M. BROWN	Management	For	For
1F.	ELECTION OF DIRECTOR: CHRISTOPHER J. COUGHLIN	Management	For	For
1G.	ELECTION OF DIRECTOR: CATHERINE M. KLEMA	Management	For	For
1H.	ELECTION OF DIRECTOR: PETER J. MCDONNELL, M.D.	Management	For	For
1I.	ELECTION OF DIRECTOR: PATRICK J. O SULLIVAN	Management	For	For
1J.	ELECTION OF DIRECTOR: BRENTON L. SAUNDERS	Management	For	For
1K.	ELECTION OF DIRECTOR: RONALD R. TAYLOR	Management	For	For
1L.	ELECTION OF DIRECTOR: FRED G. WEISS	Management	For	For
2.	TO APPROVE, IN A NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
3.	TO RECOMMEND, IN A NON-BINDING VOTE, WHETHER A SHAREHOLDER VOTE TO APPROVE THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS SHOULD OCCUR EVERY ONE, TWO OR THREE YEARS.	Management	1 Year	For
4.	TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 AND TO AUTHORIZE, IN A BINDING VOTE, THE BOARD OF DIRECTORS, ACTING THROUGH ITS AUDIT AND COMPLIANCE COMMITTEE, TO DETERMINE PRICEWATERHOUSECOOPERS LLP S REMUNERATION.	Management	For	For
5.	TO APPROVE THE MATERIAL TERMS OF THE PERFORMANCE GOALS FOR THE PURPOSES OF SECTION 162(M) UNDER THE ALLERGAN PLC 2017 ANNUAL INCENTIVE COMPENSATION PLAN.	Management	For	For
6.	TO CONSIDER A SHAREHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN, IF PROPERLY PRESENTED AT THE MEETING.	Shareholder	Against	For

ALLIQUA BIOMEDICAL, INC.

Security	019621200	Meeting Type	Annual
-----------------	-----------	---------------------	--------

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Ticker Symbol
Record Date

ALQA
28-Apr-2017

Meeting Date

23-Jun-2017

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 DAVID JOHNSON		For	For
	2 WINSTON KUNG		For	For
	3 JOSEPH LEONE		For	For
	4 GARY RESTANI		For	For
	5 JEFFREY SKLAR		For	For
	6 MARK WAGNER		For	For
	7 JEROME ZELDIS, MD, PHD.		For	For
2.	APPROVAL TO AUTHORIZE THE BOARD OF DIRECTORS OF THE COMPANY TO AMEND THE COMPANY'S CERTIFICATE OF INCORPORATION IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANY'S STOCKHOLDERS IN 2018, TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY'S COMMON STOCK, AT A RATIO IN THE RANGE OF 1-FOR-3 TO 1-FOR-13.	Management	For	For
3.	APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2014 LONG-TERM INCENTIVE PLAN, TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE UNDER THE 2014 PLAN BY AN ADDITIONAL 4,000,000 SHARES, TO A TOTAL OF 9,500,000 SHARES.	Management	For	For
4.	TO APPROVE THE ISSUANCE OF MORE THAN 19.99% OF THE COMPANY'S OUTSTANDING COMMON STOCK AT A PRICE PER SHARE LESS THAN BOOK OR MARKET VALUE TO INVESTORS WHO PARTICIPATED IN A PRIVATE PLACEMENT WHICH CLOSED ON FEBRUARY 27, 2017 PURSUANT TO THE MFN ADJUSTMENT.	Management	For	For
5.	TO APPROVE THE ISSUANCE OF SHARES OF THE COMPANY'S COMMON STOCK TO JEROME ZELDIS, M.D., PH.D., THE CHAIRMAN OF THE COMPANY'S BOARD OF DIRECTORS, PURSUANT TO THE MFN ADJUSTMENT AT A PER SHARE PURCHASE PRICE LESS THAN THE CLOSING BID PRICE OF THE COMMON STOCK ON FEBRUARY 27, 2017.	Management	For	For
6.	TO APPROVE THE ISSUANCE OF SHARES OF THE COMPANY'S COMMON STOCK ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For
7.	RATIFICATION OF THE APPOINTMENT OF MARCUM LLP AS OUR ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For
8.	AN ADVISORY VOTE ON EXECUTIVE COMPENSATION AS DISCLOSED IN THESE MATERIALS.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	02-May-2017
Record Date	10-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: MICHAEL W. BONNEY	Management	For	For
1B.	ELECTION OF DIRECTOR: JOHN M. MARAGANORE, PH.D.	Management	For	For
1C.	ELECTION OF DIRECTOR: PAUL R. SCHIMMEL, PH.D.	Management	For	For
1D.	ELECTION OF DIRECTOR: PHILLIP A. SHARP, PH.D.	Management	For	For
2.	TO APPROVE THE SECOND AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN.	Management	For	For
3.	TO APPROVE THE AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN.	Management	For	For
4.	TO APPROVE, IN A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF ALNYLAM S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RECOMMEND, IN A NON-BINDING ADVISORY VOTE, THE FREQUENCY OF ADVISORY STOCKHOLDER VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For
6.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AS ALNYLAM S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	19-May-2017
Record Date	20-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: DR. DAVID BALTIMORE	Management	For	For
1B.	ELECTION OF DIRECTOR: MR. ROBERT A. BRADWAY	Management	For	For
1C.	ELECTION OF DIRECTOR: MR. FRANCOIS DE CARBONNEL	Management	For	For
1D.	ELECTION OF DIRECTOR: MR. ROBERT A. ECKERT	Management	For	For
1E.	ELECTION OF DIRECTOR: MR. GREG C. GARLAND	Management	For	For
1F.	ELECTION OF DIRECTOR: MR. FRED HASSAN	Management	For	For
1G.	ELECTION OF DIRECTOR: DR. REBECCA M. HENDERSON	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1H.	ELECTION OF DIRECTOR: MR. FRANK C. HERRINGER	Management	For	For
1I.	ELECTION OF DIRECTOR: MR. CHARLES M. HOLLEY, JR.	Management	For	For
1J.	ELECTION OF DIRECTOR: DR. TYLER JACKS	Management	For	For
1K.	ELECTION OF DIRECTOR: MS. ELLEN J. KULLMAN	Management	For	For
1L.	ELECTION OF DIRECTOR: DR. RONALD D. SUGAR	Management	For	For
1M.	ELECTION OF DIRECTOR: DR. R. SANDERS WILLIAMS	Management	For	For
2.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	ADVISORY VOTE TO APPROVE OUR EXECUTIVE COMPENSATION.	Management	For	For
4.	ADVISORY VOTE ON THE FREQUENCY OF FUTURE STOCKHOLDER VOTES TO APPROVE EXECUTIVE COMPENSATION.	Management	1 Year	For
5.	STOCKHOLDER PROPOSAL TO ADOPT MAJORITY VOTES CAST STANDARD FOR MATTERS PRESENTED BY STOCKHOLDERS.	Shareholder	Against	For

AMICUS THERAPEUTICS, INC.

Security	03152W109	Meeting Type	Annual
Ticker Symbol	FOLD	Meeting Date	13-Jun-2017
Record Date	17-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	TED W. LOVE, M.D.	For	For
	2	ROBERT ESSNER	For	For
2.	RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017	Management	For	For
3.	APPROVE, ON AN ADVISORY BASIS, THE COMPANY S EXECUTIVE COMPENSATION	Management	For	For
4.	APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF THE VOTE ON EXECUTIVE COMPENSATION	Management	1 Year	For

ARCA BIOPHARMA, INC.

Security	00211Y407	Meeting Type	Annual
Ticker Symbol	ABIO	Meeting Date	01-Jun-2017
Record Date	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	DR. MICHAEL R. BRISTOW	For	For
	2	ROBERT E. CONWAY	For	For
2.	TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

ARDELYX, INC

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	07-Jun-2017
Record Date	12-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	ROBERT BAZEMORE	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

2	GORDON RINGOLD, PH.D.		For	For
3	RICHARD RODGERS		For	For
2.	TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG, LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017.	Management	For	For

AURIS MEDICAL HOLDING AG

Security Ticker Symbol Record Date	H03579101 EARS 10-Mar-2017	Meeting Type Meeting Date	Annual 13-Apr-2017
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF THE ANNUAL REPORT, THE FINANCIAL STATEMENTS AND THE GROUP CONSOLIDATED FINANCIAL STATEMENTS FOR THE 2016 FINANCIAL YEAR	Management	For	For
2.	DISCHARGE OF LIABILITY FOR THE MEMBERS OF THE BOARD OF DIRECTORS AND THE PERSONS ENTRUSTED WITH THE CORPORATION'S MANAGEMENT	Management	For	For
3.	APPROPRIATION OF FINANCIAL RESULTS	Management	For	For
4.1	INCREASE OF THE AUTHORIZED SHARE CAPITAL	Management	For	For
4.2	INCREASE OF THE CONDITIONAL SHARE CAPITAL FOR FINANCING PURPOSES	Management	For	For
4.3	INCREASE OF THE CONDITIONAL SHARE CAPITAL FOR EQUITY INCENTIVE PLANS	Management	Against	Against
5.1	APPROVAL OF THE COMPENSATION OF THE BOARD OF DIRECTORS	Management	For	For
5.2	APPROVAL OF THE COMPENSATION OF THE MEMBERS OF THE EXECUTIVE MANAGEMENT COMMITTEE FOR THE 2018 FINANCIAL YEAR	Management	For	For
6.1	RE-ELECTION OF THOMAS MEYER AS MEMBER AND AS CHAIRMAN OF THE BOARD OF DIRECTORS	Management	For	For
6.2	RE-ELECTION OF ARMANDO ANIDO AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.3	RE-ELECTION OF OLIVER KUBLI AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.4	RE-ELECTION OF BERNDT A. MODIG AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.5	RE-ELECTION OF ANTOINE PAPIERNIK-BERKHauer AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.6	RE-ELECTION OF CALVIN W. ROBERTS AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.7	ELECTION OF MATS PETER BLOM AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
7.1	RE-ELECTION OF ARMANDO ANIDO AS MEMBER OF THE COMPENSATION COMMITTEE	Management	For	For
7.2	RE-ELECTION OF CALVIN W. ROBERTS AS MEMBER OF THE COMPENSATION COMMITTEE	Management	For	For
8.	RE-ELECTION OF DELOITTE AG AS AUDITORS	Management	For	For
9.	RE-ELECTION OF THE INDEPENDENT PROXY	Management	For	For
10.	GENERAL INSTRUCTION ON NEW PROPOSALS OF THE BOARD OF DIRECTORS	Management	For	For

AVADEL PHARMACEUTICALS PLC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	05337M104	Meeting Type	Annual
Ticker Symbol	AVDL	Meeting Date	28-Jun-2017
Record Date	19-May-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: CRAIG R. STAPLETON	Management	For	For
1B.	ELECTION OF DIRECTOR: MICHAEL S. ANDERSON	Management	For	For
1C.	ELECTION OF DIRECTOR: FRANCIS J.T. FILDES	Management	For	For
1D.	ELECTION OF DIRECTOR: CHRISTOPHE NAVARRE	Management	For	For
1E.	ELECTION OF DIRECTOR: BENOIT VAN ASSCHE	Management	For	For
1F.	ELECTION OF DIRECTOR: PETER THORNTON	Management	For	For
2.	TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC AUDITOR AND ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 AND TO AUTHORIZE, IN A BINDING VOTE, THE AUDIT COMMITTEE OF THE BOARD TO SET THE INDEPENDENT REGISTERED PUBLIC AUDITOR AND ACCOUNTING FIRM REMUNERATION	Management	For	For
3.	TO APPROVE THE AVADEL PHARMACEUTICALS PLC 2017 OMNIBUS INCENTIVE COMPENSATION PLAN.	Management	For	For
4.	TO APPROVE THE AVADEL PHARMACEUTICALS PLC 2017 EMPLOYEE SHARE PURCHASE PLAN.	Management	For	For

BELLICUM PHARMACEUTICALS INC

Security	079481107	Meeting Type	Annual
Ticker Symbol	BLCM	Meeting Date	14-Jun-2017
Record Date	17-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 RICHARD A. FAIR		For	For
	2 REID M. HUBER, PH.D.		For	For
	3 JAMES M. DALY		For	For
2.	APPROVAL OF THE COMPANY S 2014 EQUITY INCENTIVE PLAN (THE PLAN),AS AMENDED, TO, AMONG OTHER THINGS, INCREASE THE SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 3,100,000 SHARES AND ELIMINATE THE CURRENT PROVISION IN THE PLAN THAT PERMITS THE BOARD TO REPRICE STOCK OPTIONS WITHOUT STOCKHOLDER APPROVAL.	Management	For	For
3.	RATIFICATION OF SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	05-Oct-2016
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DETERMINATION REGARDING SECOND TRANCHE MILESTONE CLOSING OF PREFERRED STOCK FINANCING	Management	For	For
2.	NOTICE OF INTERESTED PARTY TRANSACTIONS	Management	For	For
3.	GENERAL AUTHORIZING RESOLUTION	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	02-Mar-2017
Record Date	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	ELECTION OF DIRECTORS	Management	For	For
2.	GENERAL AUTHORIZING RESOLUTION	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	02-Mar-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	AMENDMENT AND RESTATEMENT OF RESTATED CERTIFICATE OF INCORPORATION	Management	For	For
2.	SERIES B PREFERRED STOCK FINANCING	Management	For	For
3.	WAIVER OF PREEMPTIVE RIGHTS	Management	For	For
4.	NOTICE OF INTERESTED PARTY TRANSACTIONS	Management	For	For
5.	APPROVAL OF INDEMNIFICATION AGREEMENTS	Management	For	For
6.	AMENDMENT OF 2013 STOCK AND OPTION GRANT PLAN	Management	For	For
7.	GENERAL AUTHORIZING RESOLUTION	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

BIOGEN INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	07-Jun-2017
Record Date	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: ALEXANDER J. DENNER	Management	For	For
1B.	ELECTION OF DIRECTOR: CAROLINE D. DORSA	Management	For	For
1C.	ELECTION OF DIRECTOR: NANCY L. LEAMING	Management	For	For
1D.	ELECTION OF DIRECTOR: RICHARD C. MULLIGAN	Management	For	For
1E.	ELECTION OF DIRECTOR: ROBERT W. PANGIA	Management	For	For
1F.	ELECTION OF DIRECTOR: STELIOS PAPADOPOULOS	Management	For	For
1G.	ELECTION OF DIRECTOR: BRIAN S. POSNER	Management	For	For
1H.	ELECTION OF DIRECTOR: ERIC K. ROWINSKY	Management	For	For
1I.	ELECTION OF DIRECTOR: LYNN SCHENK	Management	For	For
1J.	ELECTION OF DIRECTOR: STEPHEN A. SHERWIN	Management	For	For
1K.	ELECTION OF DIRECTOR: MICHEL VOUNATSOS	Management	For	For
2.	TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS BIOGEN INC. S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	SAY ON PAY - TO APPROVE AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.	Management	For	For
4.	SAY WHEN ON PAY - TO APPROVE AN ADVISORY VOTE ON THE FREQUENCY OF THE ADVISORY VOTE ON EXECUTIVE COMPENSATION.	Management	1 Year	For
5.	TO APPROVE THE BIOGEN INC. 2017 OMNIBUS EQUITY PLAN.	Management	For	For

BIOMARIN PHARMACEUTICAL INC.

Security	09061G101	Meeting Type	Annual
Ticker Symbol	BMRN	Meeting Date	06-Jun-2017
Record Date	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	JEAN-JACQUES BIENAIME	For	For
	2	WILLARD DERE	For	For
	3	MICHAEL GREY	For	For
	4	ELAINE J. HERON	For	For
	5	V. BRYAN LAWLIS	For	For
	6	ALAN J. LEWIS	For	For
	7	RICHARD A. MEIER	For	For
	8	DAVID PYOTT	For	